CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer.
CD109
Immunohistochemistry
Pancreatic cancer
Prognostic marker
Progression
Journal
Virchows Archiv : an international journal of pathology
ISSN: 1432-2307
Titre abrégé: Virchows Arch
Pays: Germany
ID NLM: 9423843
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
15
09
2021
accepted:
30
10
2021
revised:
20
10
2021
pubmed:
12
11
2021
medline:
26
4
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
CD109 is a glycosylphosphatidylinositol-anchored glycoprotein, whose expression is upregulated in some types of malignant tumors. High levels of CD109 in tumor cells have been reported to correlate with poor prognosis; however, significance of CD109 stromal expression in human malignancy has not been elucidated. In this study, we investigated the tumorigenic properties of CD109 in pancreatic ductal adenocarcinoma (PDAC). Immunohistochemical analysis of 92 PDAC surgical specimens revealed that positive CD109 expression in tumor cells was significantly associated with poor prognosis (disease-free survival, p = 0.003; overall survival, p = 0.002), and was an independent prognostic factor (disease-free survival, p = 0.0173; overall survival, p = 0.0104) in PDAC. Furthermore, CD109 expression was detected in the stroma surrounding tumor cells, similar to that of α-smooth muscle actin, a histological marker of cancer-associated fibroblasts. The stromal CD109 expression significantly correlated with tumor progression in PDAC (TNM stage, p = 0.033; N factor, p = 0.024; lymphatic invasion, p = 0.028). In addition, combined assessment of CD109 in tumor cells and stroma could identify the better prognosis group of patients from the entire patient population. In MIA PaCa-2 PDAC cell line, we demonstrated the involvement of CD109 in tumor cell motility, but not in PANC-1. Taken together, CD109 not only in the tumor cells but also in the stroma is involved in the progression and prognosis of PDAC, and may serve as a useful prognostic marker in PDAC.
Identifiants
pubmed: 34762199
doi: 10.1007/s00428-021-03230-2
pii: 10.1007/s00428-021-03230-2
doi:
Substances chimiques
Antigens, CD
0
Biomarkers, Tumor
0
CD109 protein, human
0
GPI-Linked Proteins
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-829Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Mizrahi JD, Surana R, Valle JW, Shroff RT (2020) Pancreatic cancer. Lancet 395:2008–2020
doi: 10.1016/S0140-6736(20)30974-0
Neoptolemos JP, Stochen DD, Friess H, Bassi C, Dunn JA, Hickey H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210
doi: 10.1056/NEJMoa032295
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703
doi: 10.1056/NEJMoa1304369
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R et al (2002) Cell surface antigen CD109 is a novel member of the α2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99:1683–1691
doi: 10.1182/blood.V99.5.1683
Solomon KR, Sharma P, Chan M, Morrison PT, Finberg RW (2004) CD109 represents a novel branch of the α2-macroglobulin/complement gene family. Gene 327:171–183
doi: 10.1016/j.gene.2003.11.025
Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S et al (2006) Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 20:1525–1527
doi: 10.1096/fj.05-5229fje
Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H et al (2010) Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene 29:2181–2191
doi: 10.1038/onc.2009.506
Li C, Hancock MA, Sehgal P, Zhou S, Reinhardt DP, Philip A (2016) Soluble CD109 binds TGF-β and antagonizes TGF-β signaling and responses. Biochem J 473:537–547
doi: 10.1042/BJ20141488
Zhang JM, Murakumo Y, Hagiwara S, Jiang P, Mii S, Kalyoncu E et al (2015) CD109 attenuates TGF-β1 signaling and enhances EGF signaling in SKMG-1 human glioblastoma cells. Biochem Biophys Res Commun 459:252–258
doi: 10.1016/j.bbrc.2015.02.093
Sakakura H, Mii S, Hagiwara S, Kato T, Yamamoto N, Hibi H et al (2016) CD109 is a component of exosome secreted from cultured cells. Biochem Biophys Res Commun 469:816–822
doi: 10.1016/j.bbrc.2015.12.063
Hagiwara S, Sasaki E, Hasegawa Y, Suzuki H, Nishikawa D, Beppu S et al (2021) Serum CD109 levels reflect the node metastasis status in head and neck squamous cell carcinoma. Cancer Med 10:1335–1346
doi: 10.1002/cam4.3737
Zhou S, da Silva SD, Siegel PM, Philip A (2019) CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro. Sci Rep 9:16317
doi: 10.1038/s41598-019-50694-z
Lee KY, Kuo TC, Chou CM, Hsu WJ, Lee WC, Dai JZ et al (2020) Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling. Cells 10:28
doi: 10.3390/cells10010028
Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N et al (2004) Expression of CD109 in human cancer. Oncogene 23:3716–3720
doi: 10.1038/sj.onc.1207418
Mii S, Enomoto A, Shiraki Y, Taki T, Murakumo Y, Takahashi M (2019) CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis. Pathol Int 69:249–259
doi: 10.1111/pin.12798
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M et al (2005) CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55:165–169
doi: 10.1111/j.1440-1827.2005.01807.x
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y et al (2007) High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57:719–724
doi: 10.1111/j.1440-1827.2007.02168.x
Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I et al (2008) Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 99:1916–1923
doi: 10.1111/j.1349-7006.2008.00731.x
Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S et al (2010) Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int 60:735–743
doi: 10.1111/j.1440-1827.2010.02592.x
Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M et al (2010) CD109 expression levels in malignant melanoma. J Dermatol Sci 57:140–142
doi: 10.1016/j.jdermsci.2009.11.004
Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A et al (2013) High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One 8:e84187
doi: 10.1371/journal.pone.0084187
Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J (2014) CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol 41:947–949
doi: 10.1111/1346-8138.12620
Tao J, Li H, Li Q, Yang Y (2014) CD109 is a potential target for triple negative breast cancer. Tumour Biol 35:12083–12090
doi: 10.1007/s13277-014-2509-5
Dong F, Liu F, Yan S, Liu X, Jiang Z, Liu J (2015) Elevated Expression of CD109 in esophageal squamous cell carcinoma. Pathol Oncol Res 21:1273–1275
doi: 10.1007/s12253-014-9894-3
Yokoyama M, Ichinoe M, Okina S, Sakurai Y, Nakada N, Yanagisawa N et al (2017) CD109, a negative regulator of TGF-β signaling, is a putative risk marker in diffuse large B-cell lymphoma. Int J Hematol 105:614–622
doi: 10.1007/s12185-016-2173-1
Shiraki Y, Mii S, Enomoto A, Momota H, Han YP, Kato T et al (2017) Significance of perivascular tumour cells defined by CD109 expression in progression of glioma. J Pathol 243:468–480
doi: 10.1002/path.4981
Emori M, Tsukahara T, Murata K, Sugita S, Sonoda T, Kaya M et al (2015) Prognostic impact of CD109 expression in myxofibrosarcoma. J Surg Oncol 111:975–979
doi: 10.1002/jso.23934
Chuang CH, Greenside PG, Rogers ZN, Brady JJ, Yang D, Ma RK et al (2017) Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axis. Nat Med 23:291–300
doi: 10.1038/nm.4285
Lee KY, Shueng PW, Chou CM, Lin BX, Lin MH, Kuo DY et al (2020) Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling. Cancer Sci 111:1652–1662
doi: 10.1111/cas.14373
Taki T, Shiraki Y, Enomoto A, Weng L, Chen C, Asai N et al (2020) CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-β signaling. Cancer Sci 111:4616–4628
doi: 10.1111/cas.14673
Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F (2013) Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8:2281–2308
doi: 10.1038/nprot.2013.143
Ishii G, Ochiai A, Neri S (2016) Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv Drug Deliv Rev 99:186–196
doi: 10.1016/j.addr.2015.07.007
Kalluri R (2016) The biology and function of fibroblasts in cancer. Nat Rev Cancer 16:582–598
doi: 10.1038/nrc.2016.73
Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P et al (2019) Stromal biology and therapy in pancreatic cancer: Ready for clinical translation? Gut 68:159–171
doi: 10.1136/gutjnl-2018-316451
Hatsuzawa Y, Yamaguchi K, Takanashi T, Sato I, Tamai K, Mochizuki M et al (2020) CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells. Pancreatology 20:493–500
doi: 10.1016/j.pan.2020.01.013
Mo XT, Leung TH, Tang HW, Siu MK, Wan PK, Chan KK et al (2020) CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signaling in cervical squamous cell carcinoma. Br J Cancer 123:833–843
doi: 10.1038/s41416-020-0922-7
Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pint A (2016) MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep 6:21648
doi: 10.1038/srep21648
Luo J (2021) KRAS mutation in pancreatic cancer. Semin Oncol 48:10–18